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Abstract
OBJECTIVE—To assess the association between elevated depression symptoms or antidepressant
medicine use on entry to the Diabetes Prevention Program (DPP) and during the study and the risk
of developing diabetes during the study.
RESEARCH DESIGN AND METHODS—DPP participants (n = 3,187) in three treatment arms
(intensive lifestyle [ILS], metformin [MET], and placebo [PLB]) completed the Beck Depression
Inventory (BDI) and reported their use of antidepressant medication at randomization and throughout
the study (average duration in study 3.2 years).
RESULTS—When other factors associated with the risk of developing diabetes were controlled,
elevated BDI scores at baseline or during the study were not associated with diabetes risk in any arm.
Baseline antidepressant use was associated with diabetes risk in the PLB (hazard ratio 2.25 [95% CI
1.38–3.66]) and ILS (3.48 [1.93–6.28]) arms. Continuous antidepressant use during the study
(compared with no use) was also associated with diabetes risk in the same arms (PLB 2.60 [1.37–
4.94]; ILS 3.39 [1.61–7.13]), as was intermittent antidepressant use during the study in the ILS arm
(2.07 [1.18–3.62]). Among MET arm participants, antidepressant use was not associated with
developing diabetes.
CONCLUSIONS—A strong and statistically significant association between antidepressant use and
diabetes risk in the PLB and ILS arms was not accounted for by measured confounders or mediators.
If future research finds that antidepressant use independently predicts diabetes risk, efforts to
minimize the negative effects of antidepressant agents on glycemic control should be pursued.
Address correspondence and reprint requests to Richard R. Rubin, Johns Hopkins University School of Medicine, 946 E. Piney Hill Rd.,
Monkton, MD 21111. E-mail: rrubin4@jhmi.edu.
*Members of the Diabetes Prevention Program Research Group appear in an online appendix at http://dx.doi.org/10.2337/dc07-1827.
NIH Public Access
Author Manuscript
Diabetes Care. Author manuscript; available in PMC 2008 May 8.
Published in final edited form as:
Diabetes Care. 2008 March ; 31(3): 420–426.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The concurrence of depression and diabetes is a serious problem. Among people with diabetes,
whose risk of depression is 50–100% greater than the general population (1), depression is
associated with higher complication (2) and mortality (3) rates and higher health care costs
(4). In 1674, Thomas Willis speculated that diabetes was caused by “long sorrow and other
depressions” (5). Findings consistent with Willis' hypothesis, as it applies to type 2 diabetes,
were reported recently in a meta-analysis (6), but not all studies included in the meta-analysis
reported positive findings. Some studies lacked sufficient statistical power or objective
determination of baseline diabetes status. Even studies with positive findings suggested that
they applied only to individuals with high levels of depression symptoms or to certain
demographic groups.
To our knowledge, no studies have considered the effects of elevated depression symptoms on
diabetes risk in a large sample of individuals at high risk for developing diabetes because they
have impaired glucose regulation or obesity. In addition, very few studies have identified an
independent increment in the risk of developing diabetes associated with use of antidepressant
medication (7), despite evidence suggesting that such medications may have an impact on
glucose tolerance. Tricyclics appear to contribute to weight gain (8) and to increase blood
glucose levels in patients with diabetes (9). Selective serotonin reuptake inhibitors (SSRIs) and
related agents appear to be associated with less weight gain and perhaps improve insulin
sensitivity (10).
Data from the Diabetes Prevention Program (DPP) offer an opportunity to better understand
the natural history of elevated depression symptoms, antidepressant medication, and type 2
diabetes in a large racially/ethnically diverse cohort of overweight individuals with elevated
fasting glucose and impaired glucose tolerance. The protocol included objective measures of
glucose tolerance and potential mediators of the effect of depression symptoms or
antidepressant medication on diabetes risk, including weight, weight change, physical activity,
and insulin secretion and resistance.
We reported earlier that on entry to the DPP 10.3% of participants had symptoms consistent
with at least mild depression, and 5.7% reported taking antidepressants, with 0.9% reporting
both elevated symptoms and antidepressant use (11). Depression symptoms were higher among
women and those having less education; antidepressant use was more common among women,
those having more education, and those of white race/ethnicity. During the study, the proportion
of participants taking antidepressants increased (to 8.7% at year 3), while the proportion with
elevated depression symptoms declined (to 8.4% at year 3), with no significant differences
among DPP treatment arms.
The current study was designed to determine 1) whether depression symptoms or
antidepressant medicine use were associated with progression to type 2 diabetes in the DPP
cohort, 2) if these associations varied by DPP treatment arm, and 3) whether these associations
were mediated by potential diabetes risk factors.
RESEARCH DESIGN AND METHODS
The DPP involved individuals at high risk for developing type 2 diabetes and was conducted
at 27 centers. DPP methods (12,13) and results (14) are described in detail elsewhere. The
protocol is available at http://www.bsc.gwu.edu/dpp. At each DPP center, an institutional
review board approved the protocol and all participants gave written informed consent.
This analysis is based on the 3,187 of 3,234 enrolled DPP participants who completed the Beck
Depression Inventory (BDI) at baseline. Participants were aged ≥25 years, had a BMI of ≥24
kg/m2 (≥22 kg/m2 in Asian Americans), and had a plasma glucose concentration of 95–125
mg/dl (5.3–6.9 mmol/l) in the fasting state (≤125 mg/dl in American Indians) and 140–199
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mg/dl (7.8–11.0 mmol/l) 2 h after a 75-g oral glucose load. Individuals were excluded from
the study if they were taking antidepressant medication that might contribute to weight loss
(bupropion or an SSRI at more than the lowest usual dose [i.e., >20 mg of fluoxetine or the
equivalent]) (15), if they had conditions that could seriously reduce their ability to participate
in the DPP (including major psychiatric disorders), or if they could not successfully complete
the 3-week run-in period during which participants took placebo medicines and recorded eating
and activity. Recruitment was designed to randomize approximately half the participants from
racial/ethnic minority groups.
Interventions
Eligible participants were randomly assigned to one of three interventions: standard lifestyle
recommendations plus metformin at a dose of 850 mg twice daily (MET arm), standard lifestyle
recommendations plus a placebo pill twice daily (PLB arm), or an intensive lifestyle
modification program (ILS arm). Goals for ILS participants were to achieve and maintain a
reduction of ≥7% of initial body weight through a calorie-controlled, low-fat diet and to engage
in physical activity of moderate intensity, such as brisk walking, for ≥150 min per week (16).
Outcomes
As part of a comprehensive protocol, DPP participants completed the BDI (17) and a measure
of leisure activity (18) before randomization and subsequently at each annual visit. Participants
brought all prescription medicines, including antidepressants, to each quarterly clinic visit, and
all were recorded.
Diabetes was diagnosed according to the 1997 American Diabetes Association criteria (19)
based on an annual oral glucose tolerance test or a semiannual fasting plasma glucose test. A
confirmation test was performed, usually within 6 weeks (12). Fasting insulin was measured
at annual visits with the oral glucose tolerance test. Detailed measurement methods for glucose
and insulin have been previously published (20).
We report follow-up through July 2001, after which the primary results were announced and
the interventions unmasked. This was 4 months longer than the results reported previously
(14), resulting in a total mean follow-up of 3.2 years per participant.
We identified participants with BDI scores ≥11 as having elevated depression symptoms;
others have chosen scores ranging from 10 to 16 (21–23) generally as a function of the
importance placed on depression recognition. We chose a symptom threshold toward the low
end of the severity range because we believed few severely depressed participants would pass
the screening process for eligibility in the DPP. We identified participants who had elevated
BDI scores at baseline and those who ever had elevated BDI scores during the DPP. We used
this measure of depression symptoms (rather than the absolute BDI score) because we were
interested in assessing the association between possible depression (i.e., elevated symptoms)
and diabetes risk.
Analysis
At baseline, categorical variables are reported as percentages and continuous variables as
means ± SD. χ2 tests were used to compare baseline differences in categorical variables. To
test for baseline differences among groups on continuous variables, the Wilcoxon's rank-sum
test (24) was used for those with nonnormal distributions; otherwise, the Student's t test was
used. During DPP, antidepressant use was reported quarterly and depression symptoms
annually. Mixed-effects modeling (25) was used to compare the difference in continuous
variables such as weight by antidepressant use or depression symptoms, and least-square means
with SEs were reported. For categorical variables such as sex, repeated-measures modeling
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with general estimation equation (26) was used to compare differences by antidepressant use
or elevated depression symptoms.
Cox proportional hazard models (27) were used to evaluate whether elevated depression
symptoms or taking antidepressants were associated with developing diabetes. Having elevated
depression symptoms during the DPP was defined as a time-dependent covariate: ever having
BDI score ≥11 up to each time point evaluated. Antidepressant use during DPP was also defined
as a time-dependent categorical variable up to each time point evaluated with three levels:
never used, used intermittently (at least once but not always), and used continuously (at all
visits). Time-dependent covariate analyses (28) were used to model the above covariates and
diabetes risk with adjustment for race/ethnicity and factors associated with an increased risk
of developing diabetes (age, sex, education, fasting plasma glucose at baseline, weight at
baseline, and weight change during the study).
The life-table method (29) was used to estimate cumulative diabetes incidence rates at 3 years.
These rates and the Greenwood estimate (30) of the SE were used to calculate the number of
individuals needed to treat with an antidepressant associated with one case of diabetes and its
95% CI. All analyses were performed using the Statistical Analysis System (SAS Institute,
Cary, NC).
RESULTS
At baseline (Table 1), 10.3% of DPP participants had BDI scores indicating at least mild
depression (≥11), and 5.7% were taking antidepressants. During the DPP (Table 1), intermittent
antidepressant use was reported for 7.2% of total person-years and continuous antidepressant
use for 3.2% of total person-years.
At baseline the median BDI score for all three treatment arms was 3 (interquartile range 1–7).
At follow-up the median BDI score was 2 (0–5) for the ILS arm and 2 (0–6) for the MET and
PLB arms. Elevated BDI scores at baseline and during the study were associated with 1) female
sex, 2) race/ethnicity other than non-Hispanic white, 3) less education, and 4) higher BMI,
higher fasting insulin levels, and lower levels of physical activity. Elevated BDI scores were
not related to age at baseline, but during the DPP older participants (aged ≥60 years) were less
likely to have elevated BDI scores than younger participants.
Antidepressant use on entry to the study and use during the study (Table 1) was associated with
female sex, non-Hispanic white race/ethnicity, and (on entry to the study only) more education.
In contrast to elevated depression symptoms, antidepressant use was not associated with fasting
insulin levels or physical activity level on entry to the DPP. Antidepressant use was associated
with BMI on entry to and during the study and with lower levels of physical activity during
the study. Antidepressant use at baseline was not related to age, but during the DPP older
participants (aged ≥60 years) were less likely to take these agents than younger participants.
At baseline, 7.4% of women, but only 2.0% (21 of 1,029) of men, took antidepressants. The
associations between antidepressant use and age, race/ethnicity, and education were similar
for male and female participants, but when analyzed separately these associations were no
longer significant among men, possibly due to lack of statistical power. Higher BMI at
randomization was significantly associated with antidepressant use at baseline and during the
study for women only.
When other factors associated with an increased risk of developing diabetes (age, sex, fasting
glucose, baseline weight, and weight change during the study) as well as race/ethnicity were
controlled, neither elevated BDI scores at baseline nor during the study were significantly
associated with diabetes risk in any treatment arm (see lines labeled HRa in Table 2). Leisure
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activity was not controlled because it was not associated with diabetes risk. (Absolute BDI
scores at baseline were significantly associated with diabetes risk in the ILS arm only [P =
0.04].)
Baseline antidepressant use, on the other hand, was strongly associated with diabetes risk for
participants in the PLB (hazard ratio 2.25 [95% CI 1.38–3.66]) and ILS (3.48 [1.93–6.28])
arms. Continuous antidepressant use during the study (compared with no use) was also
significantly associated with diabetes risk in the same arms (PLB hazard ratio 2.60 [95% CI
1.37–4.94]; ILS 3.39 [1.61–7.13]), as was intermittent antidepressant use during the study in
the ILS arm (hazard ratio 2.07 [95% CI 1.18–3.62]). In the PLB arm, the association between
intermittent antidepressant uses during the study and diabetes risk approached significance
(1.50 [0.97–2.33]). In the MET arm, antidepressant use was not associated with diabetes risk.
There was a significant difference between the ILS and MET arms in the association between
antidepressant medication and diabetes risk.
We further analyzed baseline antidepressant use, comparing only participants who were taking
SSRIs, selective serotonin and norepinepherine reuptake inhibitors, or serotonin modulators
with those who did not take any antidepressant, since these agents were considered less likely
to increase the risk of diabetes. The results for this subgroup, which included 78% of all those
taking antidepressants at baseline, were similar to those for all antidepressant users; taking
SSRIs or related agents at baseline was significantly associated with the risk of developing
diabetes during the DPP in the PLB and ILS arms but not in the MET arm. For this reason, our
analysis of the association between antidepressant use during the DPP and diabetes risk
included all antidepressants.
Our findings suggest that antidepressant use might have increased diabetes risk in the PLB and
ILS arms. Under this assumption, we calculated that treating 5.4 PLB participants (95% CI
3.1–24.8) or 5.2 ILS participants (3.2–15.5) with antidepressants would have caused one
additional case of diabetes 3 years later (31). We did not perform this calculation for the MET
arm, in which it would not be meaningful because there was no association between
antidepressant use and diabetes risk.
CONCLUSIONS
Elevated depression scores were not associated with diabetes risk
Elevated BDI scores (≥11, consistent with mild depression) at baseline and during the study
were not associated with diabetes risk during the DPP, despite the fact that elevated depression
symptoms were associated with several risk factors for diabetes (BMI, fasting glucose, and
lower levels of physical activity). Absolute BDI scores were weakly associated with diabetes
risk in the ILS arm only. These findings differ from the conclusions of a meta-analysis that
suggested that elevated depressive symptoms are associated with the risk of developing type
2 diabetes (6). DPP participants were selected because their risk for developing diabetes was
high and rates of developing diabetes in the DPP were 5- to 10-fold higher than those in earlier
studies included in the meta-analysis, where subjects did not have impaired glucose regulation
at baseline. In addition, the DPP cohort was relatively free of depression. At baseline, only
2.7% of participants had BDI scores indicating even moderate levels of depression (>16).
Perhaps in a population at high risk of developing diabetes, generally mild depression
symptoms were not potent enough to significantly affect overall diabetes rates. In some studies,
increased diabetes risk was seen only in those with more severe depression symptoms (6).
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Antidepressant medication was associated with diabetes risk
The present study of individuals at very high risk for developing diabetes, with excellent
ascertainment of diabetes onset and exposure to antidepressant medication, found an increased
risk of diabetes associated with antidepressant medication. Two recent studies also assessed
antidepressant-related diabetes risk. One study (7) found no increased risk of diabetes among
subjects taking antidepressant medication, but the study did not include a definitive
determination of diabetes. The other study (32) compared the risk of developing diabetes for
patients taking different antidepressants and reported that the risk associated with taking SSRIs
in addition to tricyclic antidepressants (TCAs) was greater than the risk associated with taking
TCAs alone. Since that study did not include those not taking antidepressants, the authors could
not assess the diabetes-related risk associated with taking any antidepressant.
Among psychotropic agents, only second-generation atypical antipsychotic agents have been
associated with increased diabetes risk (33). Weight gain, a known risk factor for diabetes, is
a recognized side effect of TCA use, and TCA-associated hyperglycemia has been reported in
patients who already have diabetes (9). SSRIs or related agents, taken by 78% of DPP
participants who took antidepressants, are generally considered to have less effect on weight,
with some reports that in people with type 2 diabetes they can actually contribute to lowering
weight (34) and improving insulin sensitivity (10). In contrast, SSRI use in the DPP was
associated with weight gain during the study. Use of antidepressants was still associated with
diabetes risk in the PLB and ILS arms when weight gain was controlled.
Explaining the association between antidepressant use and diabetes risk
The association between antidepressant use and diabetes risk remained significant when likely
mediators (e.g., fasting glucose, weight, and weight gain) of this association were controlled.
Thus, we are unable to say how use of antidepressants increases diabetes risk, if it does at all.
Antidepressant use could simply be a marker for the actual cause(s) of increased diabetes risk,
which may be more severe, chronic, or recurrent depression. Perhaps antidepressant users were
more severely depressed in the past or had a history of chronic or recurrent depression. If so,
the lingering effects of past depression, or the current effects of that depression, even with its
symptoms controlled by medication, could explain the association between antidepressant use
and diabetes risk. This argument depends on the presence of past moderate or severe depression
(or a history of chronic or recurrent depression) and on an effect of depression that operates
after symptoms have resolved (since these participants did not have elevated depression
symptoms) or on an unidentified continuing effect of depression not detected by our
questionnaire.
Antidepressant use was not associated with diabetes risk in the MET arm
Antidepressant use was not associated with diabetes risk in the MET arm. Although there is
no obvious explanation for this finding, it is similar to our previous report that metformin
treatment not only reduced the incidence of diabetes but also obliterated the predictive effect
of BMI (14).
Strengths and limitations
Strengths of the current study include the large, racially and ethnically diverse population; the
definitive assessment of glucose tolerance and diabetes; and the fact that data were collected
about antidepressant medication and depression symptoms. We were also able to pinpoint the
diagnosis of diabetes, a considerable advance over studies that rely on clinical records that may
not accurately capture when diabetes actually developed.
Rubin et al. Page 6
Diabetes Care. Author manuscript; available in PMC 2008 May 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The absence of data on specific antidepressants is a limitation, but use of the most commonly
used class of agents (SSRIs) was associated with diabetes risk in the PLB and ILS study arms,
just as was the use of any antidepressant. Excluding participants from the DPP if they were
taking bupropion, or SSRIs, in greater than low doses might limit the generalizabilty of our
findings, but antidepressant medication and dosage were not limited during the study, where
we still found an association between antidepressant use and diabetes risk.
We did not confirm that all patients using antidepressants were taking them for depression.
Some SSRIs and related agents are used to treat other disorders (35), but patients with these
disorders probably represent a small proportion of those taking SSRIs. TCAs are sometimes
prescribed for relief of neuropathic symptoms in patients with diabetes, but DPP participants
did not have diabetes at the outset of the study. The antidepressant bupropion is also indicated
for smoking cessation, but only 6% of DPP participants reported taking this agent.
Our categorical classification of antidepressant use, based on patient self-report, precludes an
examination of the association between incremental antidepressant dosage and diabetes risk.
We also could not determine whether chronicity of depressive symptoms or the number of past
episodes of depression were related to diabetes risk in this cohort or modulated the noted
association with antidepressant use.
Implications
Research implications—The finding of an association between antidepressant use and
diabetes risk requires replication. Ideally, future studies will examine the diabetes risk
associated with different classes of antidepressant medication and even specific agents. Such
studies will require large populations (e.g., prescription databases to obtain the necessary
sample sizes). If the association between antidepressant use and diabetes risk is replicated,
studies are needed to determine whether use of these agents is a causal risk factor for developing
diabetes or a marker of depression severity. Studies should seek to clarify the metabolic effects
of various antidepressants to determine how each agent affects diabetes risk. Comparing the
diabetes risk associated with antidepressant use to the risk associated with psychological
treatment could also be illuminating.
Clinical implications—If antidepressants prove to be an independent diabetes risk factor,
clinicians will need to consider this when prescribing depression treatment in patients at high
risk for diabetes. One possibility is to consider psychological treatment to avoid potential
iatrogenic effects of antidepressants (although limited resources may often make this
infeasible). In one study of depressed patients with diabetes who had high A1C levels, cognitive
behavioral therapy counseling was associated with improved glycemic control (36). This
suggests a potential benefit for patients at high risk for developing diabetes.
Public health implications—According to recent estimates, there are >40 million people
in the U.S. with pre-diabetes (IGT or impaired fasting glucose [37]), and this number is rising
rapidly. More than 10% of DPP participants were taking antidepressants when the study ended
in 2001. Antidepressant use in the U.S. has continued to rise, so probably at least 4 million
people in the U.S. who have pre-diabetes are taking antidepressants. If future research confirms
an etiologic role for antidepressants in diabetes, efforts to minimize the potentially negative
effects of these agents on glycemic control should be pursued.
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